Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

592 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients.
Paik JJ, Casciola-Rosen L, Shin JY, Albayda J, Tiniakou E, Leung DG, Gutierrez-Alamillo L, Perin J, Florea L, Antonescu C, Leung SG, Purwin G, Koenig A, Christopher-Stine L. Paik JJ, et al. Among authors: koenig a. Arthritis Rheumatol. 2021 May;73(5):858-865. doi: 10.1002/art.41602. Epub 2021 Mar 24. Arthritis Rheumatol. 2021. PMID: 33258553 Free PMC article.
Long-term extension study of tofacitinib in refractory dermatomyositis.
Paik JJ, Shneyderman M, Gutierrez-Alamillo L, Albayda J, Tiniakou E, Perin J, Purwin G, Leung S, Leung D, Casciola-Rosen L, Koenig AS, Christopher-Stine L. Paik JJ, et al. Arthritis Rheumatol. 2022 Feb;74(2):371-372. doi: 10.1002/art.41944. Epub 2021 Dec 28. Arthritis Rheumatol. 2022. PMID: 34369109 Free PMC article. No abstract available.
Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial.
Dougados M, van der Heijde D, Sieper J, Braun J, Maksymowych WP, Citera G, Miceli-Richard C, Wei JC, Pedersen R, Bonin R, Rahman MU, Logeart I, Wajdula J, Koenig AS, Vlahos B, Alvarez D, Bukowski JF. Dougados M, et al. Arthritis Rheumatol. 2014 Aug;66(8):2091-102. doi: 10.1002/art.38721. Arthritis Rheumatol. 2014. PMID: 24891317 Clinical Trial.
Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database.
Harnett J, Gerber R, Gruben D, Koenig AS, Chen C. Harnett J, et al. J Manag Care Spec Pharm. 2016 Dec;22(12):1457-1471. doi: 10.18553/jmcp.2016.22.12.1457. J Manag Care Spec Pharm. 2016. PMID: 27882833 Free PMC article.
OBJECTIVE: To compare characteristics, treatment patterns, and costs of patients with rheumatoid arthritis (RA) receiving tofacitinib versus the most common bDMARDs (adalimumab [ADA], etanercept [ETN], and abatacept [ABA]) following a single bDMARD in a U.S. adminis …
OBJECTIVE: To compare characteristics, treatment patterns, and costs of patients with rheumatoid arthritis (RA) receiving tofacitinib versus …
592 results